Skip Navigation

Scout Archives

Home Projects Publications Archives About Sign Up or Log In

New Antibiotic Approved by FDA

Last week, the FDA approved Zyvox (known generically as linezolid), the first in a new class of synthetic antibacterial drugs -- called oxazolidinones -- designed to treat a number of drug-resistant infections. Zyvox has proven effective in treatment of infections associated with vancomycin-resistant Enterococcus faecium (VREF) as well as hospital-acquired pneumonia and complicated skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus (MRSA). This is the first drug to be approved in over 40 years for fighting hospital-acquired infections that are resistant to antibiotics. "It comes at a time when we were literally running out of antibiotics," said Dr. Robert C. Moellering Jr., physician-in-chief of Boston's Beth Israel-Deaconness Hospital, in a recent AP news article. In an attempt to preserve the long-term effectiveness of Zyvox and discourage microbes from developing renewed resistance, some doctors are calling for cautious use of the drug for only the worst antibiotic-resistant infections. This week's In The News takes a look at this new development and its consequences for antibiotic resistant bacteria.
Archived Scout Publication URL
  • https://scout.wisc.edu/report/se/2000/0426
Language
Date of Scout Publication
April 26th, 2000
Date Of Record Creation
April 7th, 2003 at 1:46pm
Date Of Record Release
April 7th, 2003 at 1:46pm
Resource URL Clicks
3
Cumulative Rating
0

Internal

Cumulative Rating
0
Add Comment

Comments

(no comments available yet)